An exploratory analysis of C-X-C motif chemokine ligand 10 as a new biomarker of asymptomatic Leishmania infantum infection in solid-organ transplant recipients
Copyright © 2022. Published by Elsevier Ltd..
OBJECTIVE: Sensitive and less laborious assays are needed to detect asymptomatic Leishmania among solid organ transplant (SOT) recipients. Using SLA-stimulated plasma from SOT recipients living where an outbreak of Leishmania infantum occurred, we examined potential biomarkers to identify asymptomatic Leishmania infections.
METHODS: Concentrations of cytokines/chemokines in plasma from whole blood stimulated with specific Leishmania antigen (SLA) were compared against infection status as determined by a currently used cell proliferation assay.
RESULTS: Twenty-six percent (13/50) of the SOT recipients had a cell proliferation assay (CPA) indicating asymptomatic infection, and showed higher processed plasma C-X-C motif chemokine ligand 10 (CXCL10 or IP-10) concentrations than did non-infected subjects (median 2272.0 pg/ml [IQR 1570-2772] vs. 18.2 pg/ml [IQR 1-150.1]; p<0.0001). CXCL10 showed a sensitivity of 93% and a specificity of 95% compared to CPA. In addition, we demonstrated that the number of asymptomatic infections detected using CXCL10, decreased with distance from a park at the center of the mentioned outbreak.
CONCLUSION: CXCL10 in plasma from SLA-stimulated blood could be a robust biomarker of asymptomatic L. infantum infection in solid organ transplant recipients.
| Errataetall: |
CommentIn: J Infect. 2022 Aug;85(2):e44-e46. - PMID 35659546 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:84 |
|---|---|
| Enthalten in: |
The Journal of infection - 84(2022), 4 vom: 29. Apr., Seite 573-578 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Carrasco-Antón, Nerea [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Asymptomatic infection |
|---|
| Anmerkungen: |
Date Completed 13.04.2022 Date Revised 21.08.2022 published: Print-Electronic CommentIn: J Infect. 2022 Aug;85(2):e44-e46. - PMID 35659546 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2022.01.029 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336352522 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336352522 | ||
| 003 | DE-627 | ||
| 005 | 20231225231941.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2022.01.029 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1121.xml |
| 035 | |a (DE-627)NLM336352522 | ||
| 035 | |a (NLM)35101535 | ||
| 035 | |a (PII)S0163-4453(22)00029-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carrasco-Antón, Nerea |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An exploratory analysis of C-X-C motif chemokine ligand 10 as a new biomarker of asymptomatic Leishmania infantum infection in solid-organ transplant recipients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.04.2022 | ||
| 500 | |a Date Revised 21.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Infect. 2022 Aug;85(2):e44-e46. - PMID 35659546 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier Ltd. | ||
| 520 | |a OBJECTIVE: Sensitive and less laborious assays are needed to detect asymptomatic Leishmania among solid organ transplant (SOT) recipients. Using SLA-stimulated plasma from SOT recipients living where an outbreak of Leishmania infantum occurred, we examined potential biomarkers to identify asymptomatic Leishmania infections | ||
| 520 | |a METHODS: Concentrations of cytokines/chemokines in plasma from whole blood stimulated with specific Leishmania antigen (SLA) were compared against infection status as determined by a currently used cell proliferation assay | ||
| 520 | |a RESULTS: Twenty-six percent (13/50) of the SOT recipients had a cell proliferation assay (CPA) indicating asymptomatic infection, and showed higher processed plasma C-X-C motif chemokine ligand 10 (CXCL10 or IP-10) concentrations than did non-infected subjects (median 2272.0 pg/ml [IQR 1570-2772] vs. 18.2 pg/ml [IQR 1-150.1]; p<0.0001). CXCL10 showed a sensitivity of 93% and a specificity of 95% compared to CPA. In addition, we demonstrated that the number of asymptomatic infections detected using CXCL10, decreased with distance from a park at the center of the mentioned outbreak | ||
| 520 | |a CONCLUSION: CXCL10 in plasma from SLA-stimulated blood could be a robust biomarker of asymptomatic L. infantum infection in solid organ transplant recipients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Asymptomatic infection | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a CXCL10 | |
| 650 | 4 | |a IP-10 | |
| 650 | 4 | |a Leishmania | |
| 650 | 4 | |a Leishmaniasis | |
| 650 | 4 | |a Solid-organ transplant recipients | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Chemokine CXCL10 |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 700 | 1 | |a Ibarra-Meneses, Ana Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Carrillo, Eugenia |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Ruiz, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Jiménez, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Aguado, José María |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a López-Medrano, Francisco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 84(2022), 4 vom: 29. Apr., Seite 573-578 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:84 |g year:2022 |g number:4 |g day:29 |g month:04 |g pages:573-578 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2022.01.029 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 84 |j 2022 |e 4 |b 29 |c 04 |h 573-578 | ||